Rani Therapeutics (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable "bioavailability, pharmacokinetics, and weight loss to subcutaneous administration."
The company said the new data adds to the "growing body of evidence" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.
The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.
Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.
Price: 2.05, Change: +0.61, Percent Change: +42.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。